How many employees does Avalo Therapeutics, Inc. have?

Avalo Therapeutics, Inc. reported 33 employees for the fiscal year ending Dec 2025, in the annual report it filed on March 23, 2026. That is up 43.5% from a year earlier.

What is Avalo Therapeutics, Inc.'s revenue per employee?

Avalo Therapeutics, Inc. brought in $59,000 of revenue in fiscal Dec 2025, which is $2K per employee. That ranks 107 of 108 companies we track in Biotechnology, where the median is $459K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

Avalo Therapeutics, Inc. employees and revenue per employee

AVTX · Biotechnology · $718M market cap

Avalo Therapeutics, Inc. had 33 employees at the end of fiscal Dec 2025, up 43.5% from a year earlier. Revenue for the year was $59,000, down 86.6% from a year earlier, or $2K per employee. Revenue fell while headcount grew.

Employees

+43.5% YoY

Revenue

$59,000

-86.6% YoY

Revenue / employee

$2K

Peer median $459K

Rank in industry

107 of 108

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2016

Hover a year for the numbers.

AVTX employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	33	$59,000	$2K	+43.5%	-86.6%
Dec 2024	23	$441,000	$19K	+21.1%	-77.1%
Dec 2023	19	$1.9M	$101K	-5.0%	-89.3%
Dec 2022	20	$18.1M	$903K	-54.5%	+234.4%
Dec 2021	44	$5.4M	$123K	+37.5%	-19.4%
Dec 2020	32	$6.7M	$209K	+77.8%	-0.8%
Dec 2019	18	$6.8M	$375K	-71.9%	-63.2%
Dec 2018	64	$18.3M	$286K	+68.4%	-34.1%
Dec 2017	38	$27.8M	$732K	+153.3%	+2312.2%
Dec 2016	15	$1.2M	$77K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

Avalo Therapeutics, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
CGON CG Oncology Inc.	142	$4.0M	$28K	Efficient growth
STTK Shattuck Labs, Inc.	40	$1.0M	$25K	Contracting
DNTH Dianthus Therapeutics, Inc.	92	$2.0M	$22K	Hiring into decline
ABSI Absci Corporation	140	$2.8M	$20K	Contracting
INBX Inhibrx Biosciences Inc.	109	$1.3M	$12K	Leaner
NGNE Neurogene Inc.	107	$925,000	$9K	—
CLDX Celldex Therapeutics, Inc.	198	$1.5M	$8K	Hiring into decline
ARTV Artiva Biotherapeutics, Inc.	89	$251,000	$3K	—
AVTX Avalo Therapeutics, Inc.	33	$59,000	$2K	Hiring into decline

Every Healthcare company

Questions about Avalo Therapeutics, Inc.

How many employees does Avalo Therapeutics, Inc. have?: Avalo Therapeutics, Inc. reported 33 employees for the fiscal year ending Dec 2025, in the annual report it filed on March 23, 2026. That is up 43.5% from a year earlier.
What is Avalo Therapeutics, Inc.'s revenue per employee?: Avalo Therapeutics, Inc. brought in $59,000 of revenue in fiscal Dec 2025, which is $2K per employee. That ranks 107 of 108 companies we track in Biotechnology, where the median is $459K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare AVTX with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in Avalo Therapeutics, Inc.'s annual reports (Form 10-K), latest filed March 23, 2026. This is data, not a recommendation to buy or sell AVTX.